RASGRF2

Across TCGA pan-cancer cohorts, RASGRF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RASGRF2 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RASGRF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RASGRF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where RASGRF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.952	0.622	.001	30	view →
LSCC	DFS	Median	II,III,IV	0.505	0.866	<.001	28	view →
PDAC	DFS	Median	III,IV	0.312	0.834	.003	22	view →
OV	DFS	Median	All	0.586	1.000	.018	4	view →
GBM	DFS	Quartile	All	0.872	0.663	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RASGRF2–CCRCC (OS)

Open the CCRCC breakdown →